Exai Bio has developed a liquid biopsy platform that utilizes cell-free RNA profiling and artificial intelligence to detect cancer early through a simple blood draw. By analyzing orphan non-coding RNA sequences abundant in tumors, the platform provides actionable insights that enhance personalized treatment strategies for patients.
Funding
$70.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
S3Founders
Product
Problem
Current cancer detection methods often rely on late-stage diagnosis, leading to reduced treatment options and poorer patient outcomes. Traditional biopsy methods are invasive and may not always capture the full heterogeneity of the tumor. There is a need for non-invasive, early-detection methods that can provide comprehensive insights into cancer biology.
Solution
Exai Bio offers a liquid biopsy platform that leverages cell-free RNA (cfRNA) profiling and artificial intelligence to enable early cancer detection through a standard blood draw. The platform analyzes unique, tumor-associated non-coding RNA sequences (oncRNA) to identify cancer signals that may be missed by conventional methods. By applying proprietary AI algorithms to these oncRNA biomarkers, Exai Bio generates actionable insights into cancer biology, providing clinicians with information to personalize treatment strategies. The platform aims to improve early detection rates, treatment efficacy, and ultimately, patient outcomes.
Target Audience
The primary target audience includes oncologists, pathologists, and other healthcare professionals involved in cancer diagnosis, treatment, and management, as well as pharmaceutical companies developing targeted cancer therapies.
Features
- Proprietary oncRNA biomarker discovery technology targeting unique, tumor-specific non-coding RNA sequences
- Advanced AI algorithms for signal detection and pattern recognition in cfRNA profiles
- Non-invasive liquid biopsy approach using a standard blood draw
- Comprehensive cancer biology insights to inform personalized treatment strategies
- Potential for early cancer detection, enabling timely intervention